ASCO 2023
CDK4/6i in EBC: Have abema and ribo arrived in the early setting? Insights from North America and Europe
ASCO 2023
CDK4/6i in EBC: Have abema and ribo arrived in the…
Sonia Trial
ACSO 2023
Sonia trial: How does the new data change clinical…
ASCO 2023
Discussions and controversies on social-media: what is…
ASCO 2023
ADC revolution: How can the new results be integrated…
NATALEE
ASCO 2023
Expanding CDK4/6i therapy in EBC: How to select…
NATALEE, MonarchE, PENELOPE-B
ASCO 2023
CDK4/6 inhibitors in EBC: Amazing data, but longer…
PHERGain
ASCO 2023
PART1: How to de-escalate chemotherapy? What is the…
SOFT
ASCO 2023
PART2: Trying to understand optimal therapy for…
PHERGain
ASCO 2023
Chemotherapy de-escalation in HER2+ patients:…
Meta Analyses
ASCO 2023
Data from Meta-Analyses of almost 15k Patients: Who…
NATALEE
ASCO 2023
New data on Ribocilib in adjuvant setting EBC: What…
Meta-Analyses, SOFT
ASCO 2023
Young patients benefit from ovarian suppression
PHERGain
ASCO 2023
PHERGain opens the possibility to avoid chemotherapy in…
PHERgain
ASCO 2023
Response adapted, chemotherapy-free option in HER2+ EBC
ASCO 2023
TILs subtypes are associated with clinical features and…
NATALEE
ASCO 2023
More CDK4/6 options for EBC patients
PHERGain
ASCO 2023
A challenge for clinical management
NATALEE
ASCO 2023
Ribociclib has arrived in the adjuvant setting
ASCO 2023
SOC of ovarian ablation confirmed in meta-analysis.
NATALEE, MonarchE, PENELOPE-B
ASCO 2023
My EBC highlights from ASCO23
NATALEE
ASCO 2023
First data with adjuvant ribociclib
NATALEE, MonarchE, PENELOPE-B
ASCO 2023
Discussions on CDK4/6 inhibitors in EBC
PHERGain
ASCO 2023
Can we preserve our patients form chemotherapy?
ASCO 2023
Ovarian function - Ovarian suppression not necessary in…
ShortHER
ASCO 2023
10 years update on ShortHER
PHERGain
ASCO 2023
1/3 of patients with HER2+ in future without…
TORCHLIGHT
ASCO 2023
Another proof of efficacy of immunotherapy in advanced…
PENELOPE-B
ASCO 2023
Analyses of ctDNA in PENELOPE-B: Test methods are…
NATALEE
ASCO 2023
Practice changing or not quite yet?
NATALEE
ASCO 2023
Ribociclib improves iDFS
PHERGain
ASCO 2023
De-escalation of CT for early BC
PENELOPE-B
ASCO 2023
Tumor-informed ctDNA likely prognostic for relapse in…
RUBY
ASCO 2023
Checkpoint inhibition in endometrial cancer: new…
ASCO 2023
TILs in HER2+ disease - prognostic, but not enough to…
NATALEE, MonarchE
ASCO 2023
Early follow-up shows clear benefit
ASCO 2023
TILs are prognostic but not predictive in HER2+ EBC
PALMIRA
ASCO 2023
Palbociclib after Palbociclib might not be the best…
PENELOPE-B
ASCO 2023
From PENELOPE-B to SURVIVE
NeoPACT
ASCO 2023
Chemo-immunotherapeutic signals especially in HER2low…
GeparNuevo
ASCO 2023
White blood cells with increasing prognostic relevance?…
NATALEE
ASCO 2023
Czy wystarczy, aby zmienić standardy?
PHERGain
ASCO 2023
Eine Herausforderung für das klinische Management
ASCO 2023
TILs w rakach HER2+ - znaczenie rokownicze, ale nie…
ASCO 2023
TILs sind prognostisch aber nicht prädiktiv beim HER2+…
PENELOPE-B
ASCO 2023
Tumor-informed ctDNA wahrscheinlich prognostisch für…
PALMIRA
ASCO 2023
Palbociclib después de Palbociclib podría no ser la…
NATALEE, MonarchE, PENELOPE-B
ASCO 2023
I miei punti salienti di ASCO23
PHERGAIN
ASCO 2023
Response adaptierte, Chemotherapie-freie Option beim…
TORCHLIGHT
ASCO 2023
Kolejny dowód na skuteczność immunoterapii w…
ASCO 2023
Ovar Funktion - Ovarielle Supression verzichtbar bei…
NATALEE
ASCO 2023
Eine Herausforderung für viele Patienten, wenig…
NATALEE
ASCO 2023
Primele date cu ribociclib adjuvant
PHERGain
ASCO 2023
PHERGain abre la posibilidad de evitar la quimioterapia…
NATALEE
ASCO 2023
NATALEE nicht überraschend aber überzeugend positiv
PENELOPE-B
ASCO 2023
Von PENELOPE-B zur SURVIVE
PHERgain
ASCO 2023
1/3 der Patientinnen mit HER2+ zukünftig ohne…
NeoPACT
ASCO 2023
Chemo-IO Signale bei HER2low prädiktiv für Ansprechen…
ASCO 2023
SOC der ovarialen Ablation in der Metaanalyse bestätigt
ASCO 2023
TILs Subtypen sind assoziiert mit klinischen Merkmalen…
PALMIRA, MAINTAIN (ASCO22), PACE (SABCS22)
ASCO 2023
CDK4/6 i beyond CDK4/6 i: one more piece to the puzzle
18F-FES
ASCO 2023
Molecular imaging for endocrine responsivness
PreCycle
ASCO 2023
E-Health Applications in Oral Cancer Therapy
TROPiCS-02
ASCO 2023
Continued OS benefit for Sacituzumab Govitecan
TROPiCS-02; HER3-dXD; Destiny-Breast 02, 03, 04
ASCO 2023
Updates on ADCs in metastatic breast cancer
SONIA
ASCO 2023
What is the optimal therapie sequence for HR+ MBC…
PADA-1
ASCO 2023
The start of precision medicine in HR+ breast cancer
TROPiCS-02; HER3-dXD; Destiny-Breast 02, 03, 04
ASCO 2023
Aggiornamenti sugli ADC nel carcinoma mammario…
TROPiCS-02; HER3-dXD; Destiny-Breast 02, 03, 04
ASCO 2023
Mises à jour sur les ADC dans le cancer du sein…
PALMIRA, MAINTAIN (ASCO22), PACE (SABCS22)
ASCO 2023
CDK4/6i dopo CDK4/6i, un altro pezzo del puzzle: lo…
SONIA, PALMIRA, PADA-1
ASCO 2023
CDK4/6i in first line and beyond & Biomarkers
TROPICS-02, HER3 DxD
ASCO 2023
Update ADC efficacy
SONIA, PALMIRA, PADA-1
ASCO 2023
CDK4/6 Sequencing? ESR-1 not ready for prime time?…
CANKADO
ASCO 2023
The value of eHealth
ICECAP
ASCO 2023
PSA nadir 6 month after Radiotherapy is strong…
ASCO 2023
Over-staging of bone scan compared with PSMA PET/CT
PRL02
ASCO 2023
PRL-02: Intramuscular arbiraterone
TRANSPORT
ASCO 2023
Part 1: Important update on testosterone-recovery
TALAPRO-2
ASCO 2023
TALAPRO-2: Results and controversies
PEACE-1
ASCO 2023
PEACE 1 - results and controversies
LuPARP
ASCO 2023
LuPARP combination study: LuPSMA and Olaparib in mCRPC
TALAPRO-2
ASCO 2023
PAPR-inhibitors: Patient-selection matters!
REASSURE
ASCO 2023
Reassuring real-world data!
TALAPRO-2
ASCO 2023
Confirming results for PARPi in mCRPC
TRANSPORT
ASCO 2023
Part2: Important update on testosterone-recovery
ARASEC
ASCO 2023
ARASEC: ADT + Daralutamide for mHSPC
Educational Session PCA
ASCO 2023
Intensified or de-intensified therapy in mHSPC
NRG/RTOG
ASCO 2023
AI for prediction in local prostate carcinoma
DEAR
ASCO 2023
DEAR trial: real-world comparator analyses of ARIs
ASCO 2023
Metastasis-directed for prostate cancer
TALAPRO-2
ASCO 2023
Επιβεβαίωση αποτελεσμάτων για το PARPi στο mCRPC
ASCO 2023
Skelettscintigrafi ospecifikt jämfört med PSMA PET-CT
ICECAP
ASCO 2023
PSA nadir 6 månader efter radioterapi är en prognostisk…
Educational Session PCa
ASCO 2023
Intensifierad eller de-intensifierad behandling vid…
LuPARP
ASCO 2023
LuPARP studien: 177-Lu-PSMA och olaparib vid mCRPC
TALAPRO-2
ASCO 2023
PARP-inhibitors: La selección de pacientes es…
PEACE-1
ASCO 2023
Triple therapy in mCSPC - which is the ideal partner…
ASCO 2023
What is your preferred sequence in 1st line treatment…
TALAPRO-2
ASCO 2023
PARPi in PCa: more genetic testing is required as PRO…
JAVELIN BLADDER 100
ASCO 2023
Q-TWiST in the therapy of aUC
VESPER, THOR, SWOG S1011, NORSE
ASCO 2023
Best of Bladder: ddMVC increases DFS! Standard…
THOR
ASCO 2023
The beginning of a new era in urothelial cancer?!
SWOG S1011
ASCO 2023
Extent of lymphadenectomy in cystectomy
VESPER
ASCO 2023
New standard for MIBC
THOR
ASCO 2023
New SoC option for metastatic bladder cancer
EV-103
ASCO 2023
Enfortumab vedotin + pembrolizumab 1stL in…
EV-103
ASCO 2023
First line in cisplatin-ineligible advance urothelial…
THOR
ASCO 2023
FGFR inhibition
THOR
ASCO 2023
Targeted therapies in advanced urothelial cancer: The…
VESPER, THOR, SWOG S1011, NORSE
ASCO 2023
Best of Bladder: ddMVC increases DFS! Standard…
THOR
ASCO 2023
Terapias dirigidas al cáncer urotelial avanzado: ¡¿El…
THOR
ASCO 2023
Nouvelles options de soins standard pour le cancer de…
EV-103
ASCO 2023
Primera línea en cáncer urotelial avanzado no elegible…
VESPER
ASCO 2023
The efficacy of neo-adjuvant therapy (ddMVAC,…
THOR, NORSE, PROOF 302
ASCO 2023
The efficacy of FGFR targeting
Study EV-103, JAVELIN Bladder 100
ASCO 2023
Update EV/Pembro, Avelumab Maintenance
Keynote-426 CLEAR
ASCO 2023
Long term follow up in advanced renal cell cancer: Is…
CBM588
ASCO 2023
The impact of microbiome and supplements on therapy…
KEYNOTE-B61
ASCO 2023
Non ccRCC: how should we treat patients today?
CONTACT-03
ASCO 2023
Primary endpoint not reached: what do we learn from…
CONTACT-03
ASCO 2023
IO rechallenge in mRCC
Keynote-426, CLEAR
ASCO 2023
Long-term follow-up for IO/TKI in mRCC
CONTACT-03
ASCO 2023
New standard for 2nd line RCC?
KEYNOTE-B61
ASCO 2023
New data non ccRCC
Keynote-426, CLEAR
ASCO 2023
1st Line therapy RCC: which combination to choose?
KEYNOTE-426, CLEAR
ASCO 2023
Update and take home message of 1st Line mRCC
KEYNOTE-B61
ASCO 2023
Lenvatinib + pembrolizumab in non-clear cell renal cell…
CheckMate 314
ASCO 2023
News from the adjuvant
ADAURA
ASCO 2023
ADAURA: Osimertinib improves survival in the treatment…
CheckMate 816, IMpower010, KEYNOTE-671, NEOTORCH
ASCO 2023
The value of perioperative chemo-IO in rNSCLC and the…
ADAURA
ASCO 2023
A new standard of care for operated patients with…
KEYNOTE-671
ASCO 2023
Role of periopertative IO confirmed
ADAURA
ASCO 2023
ADAURA - results and controversies
KEYNOTE-671
ASCO 2023
Added benefit of perioperative chemo/IO in stage 2-3b…
ADAURA
ASCO 2023
ADAURA - Discussion closed?
ADAURA
ASCO 2023
OS benefit from EGFR receptor TKI
ADAURA
ASCO 2023
A new standard of care
EAST ENERGY
ASCO 2023
A chemo-free preop. IO strategy?
KEYNOTE-671
ASCO 2023
Which should we prefer: neoadjuvant, adjuvant or…
KEYNOTE-671, CheckMate-816
ASCO 2023
Confirmation of neoadjuvant immunotherapy
ADAURA
ASCO 2023
An imperfect analysis, but perfect results
KEYNOTE-671
ASCO 2023
Another neoadjuvant chemo/IO option
ADAURA, KEYNOTE-671
ASCO 2023
More options in the perioperative setting
ADAURA
ASCO 2023
EGFR testing necessary in the adjuvant setting
CheckMate 9LA
ASCO 2023
CheckMate 9LA: 4‑year clinical update
KEYNOTE-671
ASCO 2023
Perioperative treatment
IMpower010
ASCO 2023
Adjuvant IO in KRASm patients
KEYNOTE-671, NEOTORCH
ASCO 2023
Induction options in the perioperative setting
CheckMate 816, ADAURA
ASCO 2023
Adjuvant and neoadjuvant strategies in resectable NSCLC
KEYNOTE-671
ASCO 2023
Rolle der periopertativen IO bestätigt
CheckMate 816, ADAURA
ASCO 2023
Stratégies adjuvantes et néoadjuvantes dans le CBNPC…
KEYNOTE-671
ASCO 2023
Que devrions-nous préférer: traitement néoadjuvant,…
ADAURA, KEYNOTE-671
ASCO 2023
Más opciones en el entorno perioperatorio
KEYNOTE-671
ASCO 2023
Toegevoegde waarde van periperatief chemo-immuno bij…
ADAURA
ASCO 2023
Un nouveau standard therapeutique pour les patients…
ADAURA
ASCO 2023
ADAURA- discussie gesloten?
ASCO 2023
Zorifertinib: an option when osimertinib is not…
CodeBreaK 200
ASCO 2023
Sotorasib: clear clinical benefit, but short follow-up…
TROPION-Lung02
ASCO 2023
Does ADC + chemo + IO replace the existing concepts?
LUNAR
ASCO 2023
TTF-treatment requires further studies
KEYNOTE-789
ASCO 2023
Pembro + chemo in pts with TKI-resistant EGFRm /…
SCARLET, KontRASt-01
ASCO 2023
Update on KRASG12Cm treatment options - how to proceed?
CORRELATE
ASCO 2023
CORRELATE - a real world analysis
KEYNOTE-789
ASCO 2023
IO in EGRF positive patients post TKI
TROPION-Lung02
ASCO 2023
TROP2-ADC shows high response rates in 1L-combination…
TROPION-Lung02
ASCO 2023
ADC + ICI ± Pt-CT in patients with aNSCLC
ASCO 2023
Stopping treatment is ok
LUNAR
ASCO 2023
LUNAR: TTF medical device shows OS-benefit, but more…
ASCO 2023
Hyperfractionation - an interestingh concept, but not…
ASCO 2023
New data from another BiTE
ASCO 2023
Hyperfractionated radiotherapy for SCLC
ASCO 2023
More BiTEs, more possibilities
SWOG 1929
ASCO 2023
A positive trial with no impact
SWOG 1929
ASCO 2023
Can we incoporate biomarkers in SCLC treatment?
SWOG 1929
ASCO 2023
Treatment strategies in SCLC
SWOG 1929
ASCO 2023
Kunnen we biomarkers gebruiken om behandeling te…
ASCO 2023
Más BiTEs, más posibilidades
SWOG 1929
ASCO 2023
Stratégies de traitement dans le SCLC
IND277
ASCO 2023
No practice-changing data in mesothelioma, other…
PROspect
ASCO 2023
ONCOalert (inclusive patient advocates) consensus on…
IND227
ASCO 2023
Immune checkpoint inhibitors in malignant mesothelioma
IND227
ASCO 2023
Immun-Checkpoint-Inhibitoren beim malignen Mesotheliom
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!